The Ordinary economics: how $7 acid bottles rewrote American skincare

The product that broke the model

In September 2016, Deciem launched The Ordinary Niacinamide 10% + Zinc 1% at $5.80 USD. The same active — same concentration, same formulation rigor — sold elsewhere for $35-65 from prestige brands. Deciem hadn't found a manufacturing miracle. The brand had simply stripped out the marketing budget, the prestige packaging, the sales-channel margin, and the brand-storytelling overhead, then sold the formulation at the actual cost-plus-thin-margin price.

The American skincare industry assumed this was unsustainable. Premium brands believed the marketing budget WAS the product — that consumers paid for prestige experience as much as efficacy. Drugstore brands believed The Ordinary would burn through capital and exit. Both groups were wrong.

By 2018, The Ordinary had become the bestselling skincare brand on Sephora's app metrics. By 2020, the brand had forced a category-wide correction. By 2025, the entire structure of American skincare pricing had been rewritten — and most of the legacy mid-market brands either reformulated, repositioned, or quietly died.

This is the story of what Deciem actually did to American skincare economics, and which brands survived the correction.

The acid bombshell: $7.20 vs. $145

The product that did the most damage wasn't even the niacinamide. It was the AHA 30% + BHA 2% Peeling Solution at $7.20.

Until 2017, a 30% glycolic acid product retailed at $80-150 from established cosmetic chemistry brands. The product was sold as a professional-tier weekly treatment, with technical training material aimed at aestheticians, with packaging that emphasised the clinical formulation. Consumers were buying the prestige framing as much as the product.

The Ordinary stripped all of that out. Same 30% glycolic acid concentration. Same kind of formulation chemistry. Different price: $7.20. The product became Deciem's most discussed launch within months — partly because the price was outrageous, partly because the bright red colour made it a TikTok visual, mostly because consumers compared the INCI list to $145 prestige equivalents and discovered the formulations were near-identical.

The legacy brands had three options. They could match the price (impossible without rebuilding their cost structure). They could differentiate on something other than the active concentration (delivery system, additional ingredients, packaging, brand story). Or they could exit the active-acid category and pivot to formats Deciem couldn't easily compete in (multi-acid blends with proprietary peptide layers, time-release encapsulation, dermatologist-channel exclusivity).

Most brands picked option 2 or 3. The few that tried option 1 got crushed.

The Paula's Choice exception

Paula's Choice is the brand that survived The Ordinary best — and the reason is illustrative. Paula's Choice never positioned its 2% BHA Liquid Exfoliant as a luxury product. The brand's entire 30-year history was about evidence-based formulation at mid-market pricing — Paula Begoun had been writing books debunking prestige skincare since the early 1990s.

When The Ordinary launched, Paula's Choice was already at the price point that made sense for the formulations. The brand didn't need to reposition. It needed to defend the trust premium it had built — the consumer relationship that said "Paula's Choice is the trustworthy authority on chemical exfoliation" — and that defence held.

The same was true for Paula's Choice's Skin Perfecting 8% AHA Gel and Clear Anti-Redness Exfoliating Solution. These products competed on evidence and 25+ years of dermatology-channel relationships rather than on pure price. The Ordinary's pricing pressure didn't displace them because they weren't competing on price in the first place.

Drunk Elephant: trade-up positioning

Drunk Elephant survived by going the opposite direction. While The Ordinary stripped down, Drunk Elephant added complexity. The TLC Framboos Glycolic Night Serum layers glycolic acid with raspberry seed oil and apple seed extract — additives that justify the $90 price by complicating the formulation story.

The TLC Sukari Babyfacial does the same with a 25% AHA + 2% BHA blend in a multi-acid framework. The Ordinary couldn't compete here because Deciem's strict single-active model meant the brand wouldn't ship a multi-acid blend at the prestige tier.

What Drunk Elephant proved: there's still room in American skincare for $50-90 actives, but only if the brand commits to formulation complexity that Deciem deliberately avoids. The Ordinary's strategic constraint became a competitive opening for brands willing to do more in the formulation.

The dermatologist-channel survivors

Dr. Dennis Gross, Murad, and SkinCeuticals survived by occupying the dermatologist-channel position The Ordinary never tried to enter. The Alpha Beta Universal Daily Peel, Murad Replenishing Multi-Acid Peel, and SkinCeuticals C E Ferulic all sell through dermatology offices, dermatologist-recommended retail, and prestige sephora channels at $80-200 price points.

The Ordinary doesn't have a dermatologist-channel strategy. Deciem deliberately stayed in the direct-to-consumer Sephora channel where price-sensitivity drives purchase. That left an entire competitive space — dermatologist-recommended actives — for brands willing to invest in the slower, relationship-driven distribution model.

Naturium: the strategic copy

Naturium is the most strategically important post-Ordinary American brand. Founded in 2019 — three years after The Ordinary's launch — Naturium occupies the price tier between The Ordinary ($5-15) and Paula's Choice ($25-40). The Naturium BHA Liquid Exfoliant 2% sells at ~$20 with a formulation that adds niacinamide and centella to the salicylic acid that The Ordinary ships alone.

Naturium's positioning logic: customers who bought The Ordinary in 2017-2020 graduated to wanting more elaborate formulations as their skincare sophistication grew. Naturium catches that graduation. The brand isn't competing with The Ordinary on price — it's competing with The Ordinary on formulation depth at slightly higher pricing, betting on consumers who outgrow the single-active model.

This worked. Target acquired Naturium in 2024, and the brand is now the elevated-drugstore standard for niacinamide, vitamin C, retinol, and chemical exfoliants in American mass-market skincare.

The Inkey List parallel

The Inkey List launched in 2018 explicitly as a UK-based The Ordinary competitor. Same pricing model, same single-active framing, same Sephora distribution. The two brands now coexist in American skincare, with The Inkey List positioned slightly more accessibly (more retail availability, more conventional packaging) and The Ordinary maintaining its more clinical aesthetic.

The fact that two near-identical brands now both succeed in the same niche is itself evidence of how big the market correction was. The pre-2016 market couldn't sustain even one $7 acid brand. The post-2016 market sustains at least two, plus Naturium, plus Glossier's Solution at $34, plus several smaller indie brands.

The brands that died (or got bought)

Some brands didn't survive the correction. Cosmedix and Pevonia became dermatology-only after losing consumer relevance. Mama Mio and Bliss Skincare — once mid-market American skincare staples — got acquired and absorbed into other brand portfolios. Several legacy department-store skincare brands quietly disappeared from beauty counters as consumer preferences shifted.

The pattern: brands that competed with The Ordinary on price-without-prestige lost. Brands that competed with The Ordinary on prestige-without-evidence lost. The brands that survived found differentiated positioning — dermatologist-channel exclusivity, formulation complexity, evidence-based authority, or strategic graduation tier — that The Ordinary's strict single-active DTC model couldn't easily threaten.

What this means for shoppers

If you're building an American skincare actives routine in 2026, the strategic shopping logic looks like this:

Single-active starter actives: The Ordinary. The brand's Niacinamide 10% + Zinc 1%, Glycolic Acid 7% Toning Solution, and Hyaluronic Acid 2% + B5 are the cleanest entry points to actives at sub-$10 pricing.

Trustworthy mid-tier: Paula's Choice. The 2% BHA Liquid Exfoliant is the consensus best salicylic acid product in American skincare; the brand's authority is genuinely earned.

Multi-active formulations: Drunk Elephant for prestige-tier, Naturium for elevated-drugstore. Pick by budget.

Dermatologist-channel actives: Dr. Dennis Gross, Murad. Higher price tier, validated by clinical channel.

The Ordinary didn't kill American skincare. It restructured it — forcing the entire market to clarify what each brand was actually selling beyond the active itself. Consumers won. Some brands won. Most marketing budgets got reallocated. And $7 acids became a permanent fixture of American beauty retail, which would have been unthinkable in 2015.